Wednesday, December 13, 2017 4:34:45 PM
There shouldn't be any. To conclude that B prevented the disease in 63% of the PP population that was treated with Brilacidin one would also have to conclude that the placebo prevented the disease in 40% of the PP population given the placebo.
The company doesn't say that and they don't say it because they can't show it to be true. It would only be theoretically true if it could be shown that 100% of the people who were given the drug would have developed the disease if they weren't given the drug.
"Incidence of severe OM in Per Protocol (PP) Population: Brilacidin 36.8%, Placebo 60.0%."
Even if there was no placebo arm and the the Brilacidin results were the same I believe that the proper description of the results would be that the disease did not occur in 63% of the population, not that Brilacidin prevented the occurrence of the disease in 63% of the treated individuals. I hope you can appreciate the difference.
You know that I know diddly about this stuff, but I think the logic of the point is hard to refute.
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM